Daiwa Securities Group Inc. acquired a new stake in Gritstone bio, Inc. (NASDAQ:GRTS – Get Rating) during the 4th quarter, Holdings Channel.com reports. The firm acquired 7,655 shares of the company’s stock, valued at approximately $98,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Denali Advisors LLC acquired a new position in Gritstone bio in the fourth quarter valued at approximately $59,000. Citigroup Inc. lifted its holdings in Gritstone bio by 57.6% in the third quarter. Citigroup Inc. now owns 4,603 shares of the company’s stock valued at $50,000 after buying an additional 1,682 shares during the period. FNY Investment Advisers LLC acquired a new position in Gritstone bio in the fourth quarter valued at approximately $91,000. Hershey Trust Co. acquired a new position in Gritstone bio in the third quarter valued at approximately $95,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in Gritstone bio by 59.1% in the third quarter. BNP Paribas Arbitrage SA now owns 9,071 shares of the company’s stock valued at $98,000 after buying an additional 3,370 shares during the period. Institutional investors and hedge funds own 69.92% of the company’s stock.
Shares of NASDAQ:GRTS opened at $3.06 on Friday. Gritstone bio, Inc. has a 52 week low of $3.02 and a 52 week high of $14.42. The company has a market capitalization of $222.49 million, a PE ratio of -3.22 and a beta of 0.36. The company has a 50 day moving average price of $4.38 and a two-hundred day moving average price of $7.68.
Separately, HC Wainwright lowered their target price on shares of Gritstone bio from $24.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, March 14th.
Gritstone bio Company Profile (Get Rating)
Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
- Get a free copy of the StockNews.com research report on Gritstone bio (GRTS)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Gritstone bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone bio and related companies with MarketBeat.com's FREE daily email newsletter.